Plural Ring Hetero Atoms In The Polycyclo Ring System Patents (Class 546/197)
-
Patent number: 6552049Abstract: Compounds of the formula useful for the treatment of depression such as obsessive compulsive disorder, panic attacks, generalized anxiety disorder, social anxiety disorder, sexual dysfunction, eating disorders, obesity, addictive disorders caused by ethanol or cocaine abuse and related illnesses.Type: GrantFiled: April 24, 2002Date of Patent: April 22, 2003Assignee: WyethInventors: Gary P. Stack, Hong Gao, Elizabeth S. Gildersleeve
-
Publication number: 20030073680Abstract: The present invention provides amino ceramide-like compounds which inhibit glucosyl ceramide (GlyCer) formation by inhibiting the enzyme GlyCer synthase, thereby lowering the level of glycosphingolipids. The compounds of the present invention have improved GlcCer synthase inhibition activity and are therefore useful in therapeutic methods for treating various conditions and diseases associated with altered glycosphingolipid levels.Type: ApplicationFiled: April 29, 2002Publication date: April 17, 2003Applicant: The Regents of The University of MichiganInventors: James A. Shayman, Norman S. Radin
-
Publication number: 20030073690Abstract: Novel compounds of the formula 1Type: ApplicationFiled: May 23, 2002Publication date: April 17, 2003Inventors: Deen Tulshian, Ginny D. Ho, Lisa S. Silverman, Julius J. Matasi, Robbie L. McLeod, John A. Hey, Richard W. Chapman, Ana Bercovici, Francis M. Cuss
-
Patent number: 6544997Abstract: The present invention of compounds of formula (I) a stereochemically isomeric form thereof, an N-oxide form thereof or a pharmaceutically acceptable acid addition salt thereof, —R1—R2— is a bivalent radical of formula wherein in said bivalent radicals one or two hydrogen atoms may be substituted with C1-6alkyl or hydroxy; R3 is hydrogen or halo; R4 is hydrogen or C1-6alkyl; R5 is hydrogen or C1-6alkyl; L is C3-6cycloalkyl, oxoC5-6cycloalkyl, C2-6alkenyl, or L is a radical of formula —Alk—R6—, Alk—X—R7, —Alk—Y—C(═O)—R9, or —Alk—Y—C(═O)—NR11R12 wherein each Alk is C1-12alkanediyl; and R6 is hydrogen, amino, cyano, C1-6alkylsulfonylamino, C3-6cycloalkyl, oxoC5-6cycloalkyl, aryl or a heterocyclic ringsystem; R7 is hydrogen, C1-6alkyl, hydroxyC1-6alkyl, C3-6cycloalkyl, aryl or a heterocyclic ringsystem; X is O, S, SO2 or NR8; said R8 being hydrogen or C1-6alkyl; R9 is hydrogen, C1-6alkyl, C3-Type: GrantFiled: June 8, 2001Date of Patent: April 8, 2003Assignee: Janssen Pharmaceutica, N.V.Inventors: Jean-Paul René Marie André Bosmans, Ann Louise Gabriëlle Meulemans, Michel Anna Jozef De Cleyn, Henricus Jacobus Maria Gijsen
-
Patent number: 6541637Abstract: A process for drying paroxetine hydrochloride anhydrate comprising (A) reacting a paroxetine compound with hydrogen chloride in the presence of isopropyl alcohol and crystallizing the resulting product, to obtain paroxetine hydrochloride anhydrate, and drying the resulting paroxetine hydrochloride anhydrate at a temperature of not more than 60° C. and under normal pressure or lower in an atmosphere which does not substantially contain moisture until the content of isopropyl alcohol attains to not more than 15% by weight; and (B) further drying the paroxetine hydrochloride anhydrate at a temperature of 80° to 110°C. in an atmosphere reduced to not more than 20 mm Hg until the content of isopropyl alcohol attains to not more than 5% by weight.Type: GrantFiled: December 13, 1999Date of Patent: April 1, 2003Assignee: Sumika Fine Chemicals Co., Ltd.Inventors: Mitsuru Okatake, Taro Ishibashi, Yoshihiro Kawata
-
Publication number: 20030060472Abstract: New compounds of formula I are described: 1Type: ApplicationFiled: June 20, 2001Publication date: March 27, 2003Inventors: David Alexander Learmonth, Patricio Manuel Vieira Araujo Soares da Silva
-
Publication number: 20030050304Abstract: The present invention provides compounds of formula (I): 1Type: ApplicationFiled: June 25, 2002Publication date: March 13, 2003Inventors: William W. McWhorter, Valentina Badescu
-
Publication number: 20030045526Abstract: Compounds of the formula: 1Type: ApplicationFiled: April 23, 2002Publication date: March 6, 2003Applicant: WyethInventor: Gary P. Stack
-
Publication number: 20030040623Abstract: The present invention relates to specific photochromic h-annellated benzo[f]chromene derivatives and their use in synthetic resins of all types, especially for ophthalmic applications. In particular, the present invention relates to photochromic compounds derived from benzo[f]chromenes, which in the open form have especially long-wave absorption maxima making it possible to obtain violet to blue tints when used in phototropic glasses.Type: ApplicationFiled: May 10, 2002Publication date: February 27, 2003Inventors: Claudia Mann, Manfred Melzig, Udo Weigand
-
Patent number: 6521758Abstract: Tosylate salts are useful in purifying 4-(fluorophenyl)-3-carbinol-piperidines from the corresponding des-fluoro impurity. The purified compounds are advantageously used in paroxetine synthesis.Type: GrantFiled: May 14, 2001Date of Patent: February 18, 2003Assignee: Synthon BVInventors: Jacobus M. Lemmens, Theodorus H. A. Peters, Pavel Slanina
-
Publication number: 20030032809Abstract: Described herein are methods for manufacturing amorphous paroxetine hydrochloride by mixing a carboxylic acid salt of paroxetine with hydrogen chloride and isolating the amorphous paroxetine hydrochloride. Also described herein are methods for manufacturing substantially pure paroxetine free base and methods for obtaining paroxetine salts such as paroxetine acetate, paroxetine trifluoroacetate, and paroxetine formate. Also described are methods for preparing paroxetine carbonate, paroxetine phosphate, paroxetine sulfate, and analogous salts thereof. The paroxetine salts may be formulated for the treatment of medical disorders as described.Type: ApplicationFiled: April 25, 2002Publication date: February 13, 2003Inventors: Subhash P. Upadhyaya, Bruce Ronsen, Bryant Wojcik
-
Publication number: 20030028027Abstract: Paroxetine maleate and its preparation and use in the treatment and prevention of inter alia depression.Type: ApplicationFiled: June 17, 2002Publication date: February 6, 2003Applicant: SmithKline Beecham plcInventors: Victor Witold Jacewicz, David Alan Jones, John Man
-
Patent number: 6514967Abstract: The invention relates to compounds of the following general formula (I): in which: R1 and R2 represent a hydrogen atom, or form a ring, especially a benzene ring, R3 represents a hydrogen atom or an alkyl group, especially a methyl group, X and Y, independently of one another, represent a carbon atom, or a heteroatom such as a sulphur atom S, or a group with the formula (a) in which R4 and R5 represent a hydrogen atom or a methyl group, or R4 and R5 form a heterocycle, and their use for the preparation of a drug intended for the treatment of pathologies associated with abnormally high concentrations of extracellular glutamate.Type: GrantFiled: December 16, 1999Date of Patent: February 4, 2003Assignee: Centre National de la Recherche ScientifiqueInventors: Jean-Marc Kamenka, Isoline Caubere, Gerard Barbanel
-
Patent number: 6511976Abstract: This invention concerns the compounds of formula (I), the N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein n is zero, 1, 2, 3, 4, 5 or 6; X is CH2 or O; R1 and R2 each independently are hydrogen, C1-6alkyl, C1-6alkylcarbonyl, halomethylcarbonyl or C1-6alkyl substituted with hydroxy, C1-6alkyloxy, carboxyl, C1-6alkylcarbonyloxy, C1-6alkyloxycarbonyl or aryl; or R1 and R2 taken together with the nitrogen atom to which they are attached may form a morpholinyl ring or an optionally substituted heterocycle; R3 and R4 are both halogen; or R3 is halogen and R4 is hydrogen; or R3 is hydrogen and R4 is halogen; and aryl is phenyl or phenyl substituted with 1, 2 or 3 substituents selected from halo, hydroxy, C1-6alkyl and halomethyl. The compounds of formula (I) may be used as therapeutic agents.Type: GrantFiled: April 6, 2000Date of Patent: January 28, 2003Assignee: Jannsen Pharmaceutica, N.V.Inventors: José Ignacio Andrés-Gil, Francisco Javier Fernández-Gadea, Pilar Gil-Lopetegui, Adolfo Díaz-Martinez
-
Publication number: 20030018050Abstract: The present invention relates to indole and 2,3-dihydroindole derivatives having formula (I) 1Type: ApplicationFiled: August 16, 2002Publication date: January 23, 2003Applicant: H. Lundbeck A/SInventors: Ejner Knud Moltzen, Jens Kristian Perregaard, Ivan Mikkelsen, Garrick Paul Smith
-
Publication number: 20030018045Abstract: This invention provides compounds of Formula I having the structure 1Type: ApplicationFiled: July 2, 2002Publication date: January 23, 2003Applicant: WyethInventors: Mark Anthony Ashwell, William Ronald Solvibile, Dominick Anthony Quagliato, Albert John Molinari
-
Patent number: 6509464Abstract: Compounds of formula (I), their salts and solvates, wherein the substituents are as described herein, are FKBP inhibitors.Type: GrantFiled: October 30, 2000Date of Patent: January 21, 2003Assignee: Pfizer IncInventors: Martin J. Wythes, Michael J. Palmer, Mark I. Kemp, Malcolm C. MacKenny, Robert J. Maguire, James F. Blake, Jr.
-
Patent number: 6509339Abstract: This invention concerns the compounds of formula the N-oxide forms, the pharmaceutically acceptable acid addition salts and the stereochemically isomeric forms thereof, wherein R1 is C1-6alkyloxy, C2-6alkenyloxy or C2-6alkynyloxy; R2 is hydrogen or C1-6alkyloxy, or when taken together R1 and R2 may form a bivalent radical of formula wherein in said bivalent radicals one or two hydrogen atoms may be substituted with C1-6alkyl, R3 is hydrogen or halo; L is C3-6cycloalkyl, C5-6cycloalkanone, C2-6alkenyl optionally substituted with aryl, or L is a radical of formula -Alk-R4, -Alk-NR5R6, 1-R6-4-piperidinyl, Alk-X—R7, -Alk-Y—C(═O)—R9, or -Alk-Y—C(═O)—NR11R12 wherein each Alk is C1-12alkanediyl; R4 is hydrogen, C1-6alkylsulfonylamino, C3-6cycloalkyl, C5-6cycloalkanone, Ar-, di(Ar)methyl, Ar-oxy- or Het1; R5 is hydrogen or C1-6alkyl; R6 is Het2; R7 is hydrogen, C1-6alkyl, hydroxyC1-6alkyl, C3-6cycloalkyl, Ar or Het2; X is O, S, SO2 or NR8; said R8 being hydrogType: GrantFiled: August 20, 2001Date of Patent: January 21, 2003Assignee: Janssen Pharmaceutica N.V.Inventors: Jean-Paul René Marie Bosmans, Christopher John Love, Marc Gustaaf Celine Verdonck, Joannes Adrianus Jacobus Schuurkes
-
Patent number: 6503927Abstract: A stable amorphous paroxetine hydrochloride composition suitable as a therapeutic agent is prepared employing an aqueous solvent medium containing an acidulant and polyvinylpyrrolidone and drying the resulting solid dispersion. The preferred compositions include amorphous paroxetine hydrochloride, polyvinylpyrrolidone and citric acid.Type: GrantFiled: October 28, 1999Date of Patent: January 7, 2003Assignee: Pentech Pharmaceuticals, Inc.Inventors: Bruce Ronsen, Yogesh D. Sadhale, Ragab El-Rashidy
-
Publication number: 20030004188Abstract: Invented is paroxetine hydrochloride anhydrate in Form B and paroxetine hydrochloride anhydrate in Form D. Also invented are pharmaceutical formulations comprising these compounds and methods of using these compounds in therapy.Type: ApplicationFiled: August 12, 2002Publication date: January 2, 2003Applicant: SmithKline Beecham CorporationInventors: Neal Ward, Victor Witold Jacewicz
-
Patent number: 6500846Abstract: The present invention relates to a novel flavone derivative, pharmaceutically acceptable salt, hydrate, solvate and isomer thereof which is useful as an inhibitor against Cyclin Dependent Kinase (CDK), a process for preparation thereof, and a composition of anti-cancer agent or agent for treating neurodegenerative disease comprising this compound as an active ingredient.Type: GrantFiled: March 1, 2001Date of Patent: December 31, 2002Assignee: LG Chemical, Ltd.Inventors: Chang Yong Hong, Tae Sik Park, Young Kwan Kim, Jin Ho Lee, Jong Hyun Kim, Dong Myung Kim, Ho Sun Son, Sang Woong Kim, Eunice Eun Kyeong Kim
-
Patent number: 6500818Abstract: Compounds having the following formula wherein L, M, R2, R3, R4, R5, R6, R7, X1 and X2 are as defined in the specification, pharmaceutically-acceptable salt thereof, useful for treating depression, anxiety, asthma, rheumatoid arthritis, Alzheimer's disease, cancer, schizophrenia, oedema, allergic rhinitis, inflammation, pain, gastrointestinal-hypermotility, emesis, Huntington's disease, psychoses, hypertension, migraine, bladder hypermotility, or urticaria, compositions including such compounds and processes for making such compounds.Type: GrantFiled: March 30, 2001Date of Patent: December 31, 2002Assignee: Astrazeneca ABInventors: Peter Robert Bernstein, Robert Frank Dedinas, Cyrus John Ohnmacht, Keith Russell
-
Publication number: 20020198387Abstract: A process for producing a paroxetine represented by the following formula (4), which comprises reacting an N-alkylpiperidine represented by the following general formula (1) with a haloformic acid ester represented by the general formula (2) to prepare an alkoxycarbonylpiperidine represented by the general formula (3), and hydrolyzing the alkoxycarbonylpiperidine under alkaline conditions: 1Type: ApplicationFiled: May 30, 2002Publication date: December 26, 2002Applicant: ASAHI GLASS COMPANY LTD.Inventors: Shu-zhong Wang, Yasushi Matsumura
-
Publication number: 20020193401Abstract: Compounds of the formula 1Type: ApplicationFiled: April 25, 2002Publication date: December 19, 2002Applicant: WyethInventors: Megan Tran, Gary P. Stack
-
Publication number: 20020193406Abstract: Piperidine compounds, processes for preparing them, pharmaceutical compositions comprising them and their use in therapy are disclosed.Type: ApplicationFiled: June 18, 2002Publication date: December 19, 2002Applicant: SmithKline Beecham plcInventors: Andrew Simon Craig, Victor Witold Jacewicz, Michael Urquhart
-
Publication number: 20020193400Abstract: Compounds of the formula 1Type: ApplicationFiled: April 23, 2002Publication date: December 19, 2002Applicant: WyethInventors: George E.M. Husbands, Gary P. Stack, Richard E. Mewshaw, Ian A. Cliffe
-
Patent number: 6495568Abstract: Compounds of formula (I): or pharmaceutically or veterinarily acceptable salts thereof, or pharmaceutically or veterinarily acceptable solvates of either entity, wherein the broken line represents an optional bond; A is C or CH; B is CH2, O or absent; R1 and R2 are each independently selected from hydrogen, C1 to C6 alkyl optionally substituted with C1 to C4 alkoxy or phenyl, and C1 to C6 alkenyl; or, together with the carbon atom to which they are attached, form a C3 to C6 cycloalkyl group which optionally incorporates a heteroatom linkage selected from O, SO, SO2 and NR6 or which is optionally benzo-fused; R3 is hydrogen, halo, R7 or OR7; R4 is hydrogen, C1 to C4 alkyl, C1 to C4 alkoxy, trifluoromethyl or halo; R6 is hydrogen or C1 to C4 alkyl; R7 is an optionally substituted monocyclic or bicyclic ring system; m is 1 or 2; and n is 0, 1 or 2; with the proviso that B is not O when A is C; are MMP inhibitors useful in the treatment of, inter alia, tissue ulceration, wound repair and skin diType: GrantFiled: October 12, 2001Date of Patent: December 17, 2002Assignee: Warner-Lambert CompanyInventors: Kevin Neil Dack, Gavin Alistair Whitlock
-
Patent number: 6495549Abstract: Compounds of formula (I), their salts and solvates, wherein the substituents are as described herein, are FKBP inhibitors.Type: GrantFiled: October 30, 2000Date of Patent: December 17, 2002Assignee: Pfizer IncInventors: Martin J. Wythes, Michael J. Palmer, Mark I. Kemp, Malcolm C. MacKenny, Robert J. Maguire, James F. Blake, Jr.
-
Patent number: 6492394Abstract: A compound of the Formula (I): wherein Z, R1, R, and Ar2 are as defined in the specification. This invention also relates to sulfonamide compounds of the Formula (I) that are inhibitors of procollagen C-proteinase, pharmaceutical compositions containing them, methods for their use, and methods for preparing the compounds.Type: GrantFiled: December 22, 1999Date of Patent: December 10, 2002Assignee: Syntex (U.S.A.) LLCInventors: Roland Joseph Billledeau, Chris Allen Broka, Jeffrey Allen Campbell, Jian Jeffrey Chen, Sharon Marie Dankwardt, Nancy Delaet, Leslie Ann Robinson, Keith Adrian Murray Walker
-
Publication number: 20020183310Abstract: This invention provides estrogen receptor modulators of formula 1, having the structure 1Type: ApplicationFiled: April 15, 2002Publication date: December 5, 2002Applicant: WyethInventors: Christopher P. Miller, Michael D. Collini, Heather A. Harris, James C. Keith
-
Publication number: 20020183354Abstract: Compounds of the formula: 1Type: ApplicationFiled: April 25, 2002Publication date: December 5, 2002Applicant: WyethInventors: Megan Tran, Gary P. Stack
-
Publication number: 20020183353Abstract: Compounds of the formula 1Type: ApplicationFiled: April 24, 2002Publication date: December 5, 2002Applicant: WyethInventors: Gary P. Stack, Hong Gao, Elizabeth S. Gildersleeve
-
Patent number: 6479517Abstract: This invention relates to the fields of pharmaceutical and organic chemistry and provides novel phosphorous-containing benzothiophene compounds which are useful for the treatment of the various medical indications associated with post-menopausal syndrome, as well as estrogen dependent diseases including cancer of the breast, uterus and cervix. The present invention further relates to intermediate compounds and processes useful for preparing the pharmaceutically active compounds of the present invention, and pharmaceutical compositions.Type: GrantFiled: February 28, 1995Date of Patent: November 12, 2002Assignee: Eli Lilly and CompanyInventors: Henry U. Bryant, Jeffrey A. Dodge, Jeffrey S. Nissen
-
Patent number: 6476035Abstract: The present invention relates to indole and 2,3-dihydroindole derivatives having formula (I) or any of its any of its enantiometers or any mixture thereof, or an acid addition salt thereof, wherein A, R1, R2, R3, W, X, Y and Z are as described in the description. The compounds are potent serotonin reuptake inhibitors and have 5-HT1A receptor antagonistic activity.Type: GrantFiled: January 25, 2000Date of Patent: November 5, 2002Inventors: Ejner Knud Moltzen, Jens Kristian Perregaard, Ivan Mikkelsen, Garrick Paul Smith
-
Patent number: 6476227Abstract: A piperidine derivative, which can be used as an intermediate for pharmaceuticals such as paroxetine useful as antidepressants, represented by the general formula (I): wherein R1 is hydrogen atom, benzyloxycarbonyl group or tert-butoxycarbonyl group; R2 is hydroxymethyl group, an alkylsulfonyloxymethyl group having an alkyl moiety of 1 to 2 carbon atoms, phenylsulfonyloxymethyl group which may have methyl group at the 4-position, (3,4-methylenedioxyphenyl)oxymethyl group, carboxyl group or —CO2R7 group in which R7 is an alkyl group having 1 to 5 carbon atoms, and Z is methylene group or carbonyl group, with proviso that, (A) when R1 is benzyloxycarbonyl group or tert-butoxycarbonyl group, then R2 is hydroxymethyl group, an alkylsulfonyloxymethyl group having an alkyl moiety of 1 to 2 carbon atoms, phenylsulfonyloxymethyl group which may have methyl group at the 4-position or (3,4-methylenedioxyphenyl)oxymethyl group, and Z is methylene group; or (B) when R1 is hydrogen atom and Z is caType: GrantFiled: April 14, 2000Date of Patent: November 5, 2002Assignee: Sumika Fine Chemicals Co., Ltd.Inventors: Kiyoshi Sugi, Nobushige Itaya, Tadashi Katsura, Masami Igi, Shigeya Yamazaki, Taro Ishibashi, Teiji Yamaoka, Yoshihiro Kawada, Yayoi Tagami
-
Patent number: 6472394Abstract: Disclosed are compounds represented by structural formula I: or a pharmaceutically acceptable salt, ester or solvate thereof, wherein W is R1—CR3R12NR4C(O)— or R11C(O)NR4—; the dotted line is an optional double bond; X is —CHR8—, —C(O)—, or —C(═NOR9)—; Y is R1 is optionally substituted cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl or heterocycloalkyl-alkyl; R2 is optionally substituted aryl or heteroaryl; R3 is alkyl, aryl or heteroaryl; R4 and R12 are H or alkyl; R8 is H, alkyl or alkoxyalkyl; R9 is H, alkyl or arylalkyl; R10 is H, alkyl or aryl; R11 is or, when R2 is R6-heteroaryl or R10 is not H, R11 can also be R5-phenylalkyl; n is 1-3 and m is 1-5; and R14 is 1-3 substituents selected from H, alkyl, halogen, —OH, alkoxy and CF3; and pharmaceutical compositions containing the compounds and methods of using the compounds in the trType: GrantFiled: December 17, 2001Date of Patent: October 29, 2002Assignee: Schering CorporationInventors: Brian A. McKittrick, Jing Su, John W. Clader, Shengjian Li, Guihau Guo
-
Patent number: 6469029Abstract: The present invention is directed to non-peptidic factor Xa inhibitors which are useful for the treatment of arterial and venous thrombotic occlusive disorders, inflammation, cancer, and neurodegenerative diseases. The factor Xa inhibitors provide compounds having Formula I: or pharmaceutically acceptable salts thereof; wherein Q is phenyl, benzyl, pyridyl, thienyl, indolyl, quinolinyl, benzothienyl, biphenylyl, or imidazolyl; any of which can include one or more optional substituents independently selected from halo, trifluoromethyl, hydroxy, amino, nitro, cyano, C1-3 alkoxy, C1-3 alkyl, methylenedioxy, carboxamido, acetamido, or amidino; X is methylene, carbonyl, or sulfonyl; Z is methylene, ethylene, or propylene; M is methylene or ethylene; and R1 R2 and R3 are independently hydrogen or C1-3 alkyl.Type: GrantFiled: September 13, 2000Date of Patent: October 22, 2002Assignee: 3-Dimensional Pharmaceuticals, Inc.Inventors: Scott C. Miller, Juan José Marugán Sánchez, Kristin D. Haslow, Jonathan Hall
-
Publication number: 20020151567Abstract: The present invention provides a process for preparing N-methylparoxetine, an intermediate in the synthesis of paroxetine, by reacting sesamol-tetrabutylammonium salt with CIPMA. The synthesis of the intermediate in the prior are resulted in a particularly low yield. The use of the sesamol-tetrabutylammonium salt increases the yield by more than three folds over the prior art. The present invention is not limited to the synthesis of N-methylparoxetine, but also includes other similar compounds.Type: ApplicationFiled: February 2, 2002Publication date: October 17, 2002Inventor: Nina Finkelstein
-
Publication number: 20020151716Abstract: The synthesis of paroxetine can be made more convenient by using a solvent system comprising an aliphatic alcohol and a hydrocarbon co-solvent. The solvent system is used particularly in the hydrolysis of paroxetine phenylcarbamate and preferably uses butanol and toluene as the system.Type: ApplicationFiled: February 15, 2002Publication date: October 17, 2002Inventors: Jacobus M. Lemmens, Theodorus H. A. Peters, Frantisek Picha
-
Publication number: 20020147219Abstract: The invention relates to new compounds of formula I 1Type: ApplicationFiled: October 16, 2001Publication date: October 10, 2002Inventors: Horst Dollinger, Franz Esser, Birgit Jung, Kurt Schromm, Georg Speck
-
Patent number: 6462041Abstract: The present invention is directed to gambogic acid, analogs and derivatives thereof, represented by the general Formulae I-III: wherein R1-R5 are defined herein. The present invention also relates to the discovery that compounds having Formula I-III are activators of caspases and inducers of apoptosis. Therefore, the activators of caspases and inducers of apoptosis of this invention can be used to induce cell death in a variety of clinical conditions in which uncontrolled cell growth and spread of abnormal cells occurs.Type: GrantFiled: February 1, 2000Date of Patent: October 8, 2002Assignee: Cytovia, Inc.Inventors: Sui Xiong Cai, Han-Zhong Zhang, Yan Wang, Ben Tseng, Shailaja Kasibhatla, John A. Drewe
-
Patent number: 6458785Abstract: Selected amino acid hydroxyethylamino sulfonamide compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease. The present invention relates to retroviral protease inhibitors and, more particularly, relates to selected novel compounds, composition and method for inhibiting retroviral proteases, such as human immunodeficiency virus (HIV) protease, prophylactically preventing retroviral infection or the spread of a retrovirus, and treatment of a retroviral infection.Type: GrantFiled: April 18, 2001Date of Patent: October 1, 2002Assignee: G. D. SearleInventors: Daniel P Getman, Gary A. DeCrescenzo, John N. Freskos, Michael L. Vazquez, James A. Sikorski, Balekudru Devadas, Srinivasan Nagarajan, David L. Brown, Joseph J. McDonald
-
Publication number: 20020137938Abstract: A process for the preparation of a carbamate of formula (1): 1Type: ApplicationFiled: March 27, 2002Publication date: September 26, 2002Applicant: SmithKlineBeecham plcInventor: Edward Lucas
-
Publication number: 20020133011Abstract: 1Type: ApplicationFiled: May 3, 2002Publication date: September 19, 2002Applicant: SmithKline Beecham plcInventors: Victor Witold Jacewicz, Marvin Sungwhan Yu, Evgeny Shapiro
-
Patent number: 6451816Abstract: The invention relates to the use of pharmacologically valuable pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides according to general formula (I) in the treatment of tumors or for immunosuppression.Type: GrantFiled: December 18, 1998Date of Patent: September 17, 2002Assignee: Klinge Pharma GmbHInventors: Elfi Biedermann, Max Hasmann, Roland Löser, Benno Rattel, Friedemann Reiter, Barbara Schein, Klaus Seibel, Klaus Vogt
-
Patent number: 6448243Abstract: A novel 1,4-substituted cyclic amine derivative represented by the following formula or a pharmacologically acceptable salt thereof: (wherein A, B, C, D, T, Y and Z represent each methine or nitrogen; R1, R2, R3, R4 and R5 represent each a substituent; n represents 0 or an integer of 1 to 3; m represents 0 or an integer of 1 to 6; and p represents an integer of 1 to 3.) The compound has a serotonin antagonism and is clinically useful as medicament, in particular, for treating, ameliorating and preventing spastic paralysis or central muscle relaxants for ameliorating myotonia.Type: GrantFiled: August 11, 1999Date of Patent: September 10, 2002Assignee: Eisai Co., Ltd.Inventors: Noritaka Kitazawa, Kohshi Ueno, Keiko Takahashi, Teiji Kimura, Atsushi Sasaki, Koki Kawano, Tadashi Okabe, Makoto Komatsu, Manabu Matsunaga, Atsuhiko Kubota
-
Patent number: 6444685Abstract: This invention provides compounds of Formula I having the structure wherein R1, R2, R3, R4, W, X, and Y are as defined hereinbefore or a pharmaceutically acceptable salt thereof, which are useful in treating metabolic disorders related to insulin resistance or hyperglycemia.Type: GrantFiled: July 12, 2001Date of Patent: September 3, 2002Assignee: WyethInventors: Fuk-Wah Sum, Michael Sotirios Malamas
-
Patent number: 6444822Abstract: Described herein is the process for the preparation of 3-substituted 4-phenyl-piperidine derivatives of formula (I) in which X is selected from H and F, and R is selected from the group consisting of H, C1-C6 alkyl, C3-C6 alkenyl, and benzyl, comprising three steps starting from the monoamide of malonic acid and cinnamic aldehyde, or derivatives thereof.Type: GrantFiled: July 28, 2000Date of Patent: September 3, 2002Assignee: Chemi S.p.A.Inventors: Lorenzo De Ferra, Pietro Massardo, Oreste Piccolo, Giorgio Cignarella
-
Patent number: 6440899Abstract: Cyclohexenonedioxothiochromanoyl derivatives of the formula I where X is oxygen, sulfur, S═O, S(═O)2, CR4R5, C═O or C═NR6, the other substituents are as defined in the specification, and and agriculturally useful salts thereof; processes for preparing the cyclohexenonedioxotheiochromanoyl derivatives; compositions comprising them, and the use of these derivatives or of compositions comprising them for controling undesirable piants.Type: GrantFiled: October 30, 2000Date of Patent: August 27, 2002Assignee: BASF AktiengesellschaftInventors: Matthias Witschel, Klaus Langemann, Wolfgang von Deyn, Ulf Misslitz, Ernst Baumann, Stefan Engel, Guido Mayer, Ulf Neidlein, Oliver Wagner, Roland Götz, Martina Otten, Karl-Otto Westphalen, Helmut Walter
-
Patent number: 6436956Abstract: Paroxetine hydrochloride anhydrous designated as Form IV having at least one, some or all of the following characteristics: a) Infrared spectra as shown in FIG. 1 and 2, b) A X-ray powder diffraction pattern as shown in Schedule “C”, c) A melting point of between about 80°0 C. to about 95° C.Type: GrantFiled: November 24, 1997Date of Patent: August 20, 2002Assignee: Brantford Chemicals Inc.Inventors: K. S. Keshava Murthy, Allan Rey, Gamini Weeratunga